Fluvoxamine vs Placebo and Time to Sustained Recovery From Mild or Moderate COVID-19
Jan 12, 2023
15:01
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Susanna Naggie, MD, vice dean for research at Duke University's School of Medicine, discusses the ACTIV-6 trial of fluvoxamine for outpatient treatment of COVID-19 and outlines the role of platform trials during the pandemic. Hosted by JAMA Deputy Editor and Editorial Director for Equity Preeti Malani, MD, MSJ.
JAMA Author Interviews